.png)
4 months ago
24
The Supreme Court has blocked a nationwide settlement that would have seen the families of OxyContin victims handed billions - after ruling the payout would have shielded members of the Sackler family who own drug maker Purdue Pharma.
After deliberating for more than six months, the justices in a 5-4 vote blocked an agreement hammered out with state and local governments and victims.
The judges agreed with the Justice Department which argued that the Sacklers, who earned tens of billions of dollars flooding the country with highly addictive opioids, should not gain sweeping legal protection in the controversial deal.
The decision reversed a ruling that had upheld the plan to give the Sackler's immunity in exchange for paying up to $6 billion to settle thousands of lawsuits accusing the company of unlawful misleading marketing of OxyContin.
The settlement gave the families of Raymond Sackler and Mortimer Sackler protection from all future civil claims, effectively protecting their other assets from opioid-related lawsuits.
The Sacklers would have also given up ownership of the company but retained billions more.
The agreement provided that the company would emerge from bankruptcy as a different entity, with its profits used for treatment and prevention.
A pharmacist holds a bottle OxyContin made by Purdue Pharma at a pharmacy in Provo, Utah, U.S., May 9, 2019
After deliberating for more than six months, the justices in a 5-4 vote blocked an agreement hammered out with state and local governments and victims
The Justice Department, acting as a bankruptcy watchdog body known as the US Trustee, accused the Sacklers of withdrawing $11 billion from Purdue Pharma over the decade before the company filed for bankruptcy protection.
Justice Neil Gorsuch, writing for the majority, said 'nothing in present law authorizes the Sackler discharge.'
Justices Brett Kavanaugh, Ketanji Brown Jackson, Elena Kagan and Sonia Sotomayor dissented.
'Opioid victims and other future victims of mass torts will suffer greatly in the wake of today's unfortunate and destabilizing decision,' Kavanaugh wrote.
Purdue filed for Chapter 11 bankruptcy in 2019 to address its debts, nearly all of which stemmed from the thousands of lawsuits.
The suits allege that OxyContin helped kickstart an opioid epidemic that has caused more than half a million U.S. overdose deaths over two decades.
Edward Neiger, a lawyer representing more than 60,000 overdose victims, said: 'Today's Supreme Court ruling marks a major setback for the families who lost loved ones to overdose and for those still struggling with addiction.
'The Purdue plan was a victim-centered plan that would provide billions of dollars to the states to be used exclusively to abate the opioid crisis and $750 million for victims of the crisis, so that they could begin to rebuild their lives.
'As a result of the senseless three-year crusade by the government against the plan, thousands of people died of overdose, and today's decision will lead to more needless overdose deaths.'
At issue in the case was whether bankruptcy law lets Purdue's restructuring include legal protections for the members of the Sackler family, who have not filed for personal bankruptcy.
The Sacklers have been given immunity from civil lawsuits over their role in the opioid crisis. Dr Richard Sackler, standing second from left and Jonathan Sackler standing second from right. Seated is co-founder Raymond and his wife Beverly Sackler
Headquarters of Purdue Pharma LP, the maker of the painkiller OxyContin, in Stamford, Connecticut, September 16, 2019
Dr Mortimer Sackler & Dame Theresa Sackler attend a Cartier Dinner on 24 May 2004
The settlement gave the families of Raymond Sackler and Mortimer Sackler, seen here, protection from all future civil claims
These so-called 'non-debtor releases' originally arose in the context of asbestos litigation, but their use has been expanded by companies looking to use such protections as a bargaining chip.
The Connecticut-based company estimates that its bankruptcy settlement, approved by a judge in 2021, would provide $10 billion in value to its creditors, including state and local governments, individual victims of addiction, hospitals and others who have sued the company.
The court put the settlement on hold last summer in response to objections from the Biden administration. It's unclear what happens next.
Ed Bisch's 18-year-old son Eddie, died from an overdose after taking OxyContin in Philadelphia in 2001.
The older Bisch, who lives in New Jersey, has been speaking out against Purdue and Sackler family members ever since and is part of a relatively small but vocal group of victims and family members who opposed the settlement.
'This is a step toward justice. It was outrageous what they were trying to get away with,' he said on Thursday.
'They have made a mockery of the justice system and then they tried to make a mockery of the bankruptcy system.'
He said he would have accepted the deal if he thought it would have made a dent in the opioid crisis.
He's now calling on the Department of Justice to seek criminal charges against Sackler family members.
OxyContin first hit the market in 1996, and Purdue Pharma's aggressive marketing of it is often cited as a catalyst of the nationwide opioid epidemic, with doctors persuaded to prescribe painkillers with less regard for addiction dangers.
Cardboard gravestones with the names of victims of opioid abuse outside a courtroom in New York City in 2021
The drug and the company became synonymous with the crisis, even though the majority of pills being prescribed and used were generic drugs.
Opioid-related overdose deaths have continued to climb, hitting 80,000 in recent years. Most of those are from fentanyl and other synthetic drugs.
Arguing the case in December, Deputy Solicitor General Curtis Gannon outlined the Biden administration's objections to the deal.
'It permits the Sacklers to decide how much they're going to contribute,' Gannon said. 'It grants the Sacklers the functional equivalent of a discharge.'
But Gregory Garre, representing Purdue Pharma, said rejecting the settlement could lead to years of litigation and leave victims with no compensation at all.
Purdue's bankruptcy filing resulted directly from the massive, country-wide litigation against it and other major drugmakers and pharmacy companies for knowingly fomenting the addiction crisis.
The drug and the company became synonymous with the crisis, even though the majority of pills being prescribed and used were generic drugs
Jen Trejo holds a photo of her son Christopher as she is comforted outside the Supreme Court where signs in the shape of grave headstones, with information on people who died from using OxyContin, line a security fence, Monday, Dec. 4, 2023
Under the March 2022 settlement, the Sacklers were 'absolutely, unconditionally, irrevocably, fully, finally, forever and permanently' released from further legal liability.
The opioid epidemic has caused more than 500,000 overdose deaths in the United States over two decades, authorities say.
Purdue and other opioid makers were accused of encouraging free-wheeling prescription of their products through aggressive marketing tactics while hiding how addictive the drugs are.
Facing an avalanche of litigation, in 2021 Purdue pled guilty to three criminal charges over its marketing of OxyContin.
The Purdue Pharma settlement would have ranked among the largest reached by drug companies, wholesalers and pharmacies to resolve epidemic-related lawsuits filed by state, local and Native American tribal governments and others. Those settlements have totaled more than $50 billion.
But the Purdue Pharma settlement would have been only the second so far to include direct payments to victims from a $750 million pool. Payouts would have ranged from about $3,500 to $48,000.
Sackler family members no longer are on the company's board, and they have not received payouts from it since before Purdue Pharma entered bankruptcy.
In the decade before that, though, they were paid more than $10 billion, about half of which family members said went to pay taxes.
WHO ARE THE SACKLERS?
Purdue Pharma, which is run by some members of the wealthy Sackler family, has made tens of billions on opioid sales. Here is a breakdown of who the Sacklers are, including those who have and haven't been involved in Purdue Pharma:
ARTHUR SACKLER
Arthur, a doctor and psychiatrist, founded a research laboratory in 1938, but Arthur's real genius was in marketing and he leveraged it to sell a number of medications, including the anti-anxiety drug, Valium.
He and his younger brothers Mortimer and Raymond owned a small pharma company called Purdue Frederick that they purchased in 1952. That company produced betadine and earwax.
Arthur remained a relatively silent partner in the old Purdue and died in 1987 before it became the company we know it as today.
He never saw any of Purdue's OxyContin profits.
He donated the funds to open a number of medical education programs, libraries and museums.
Arthur was inducted into the Medical Marketing Hall of Fame upon his death in 1987.
After his death in 1987, his brothers bought Arthur's portion of the company.
One of his four children, daughter Elizabeth, has largely taken over his philanthropy work.
Arthur and his heirs have had no involvement in Purdue Pharma or with OxyContin.
MORTIMER SACKLER
Mortimer was an American physician and psychiatrist.
He and his brothers, the older Arthur and the younger Raymond published prolific medical research before buying a number of pharmaceutical companies, including, in 1952, Purdue Frederick.
After Arthur's death Mortimer and Raymond bought out his descendants' share of Purdue Frederick, and in 1991 they created the company that would become a pain management giant we now know, Purdue Pharma.
Mortimer became a lavish arts patron, known for equally extravagant donations and parties, beginning in the 1970s.
He died in 2010.
RAYMOND SACKLER
Raymond was a doctor like his older brothers, and the three were partners in all things until each of their deaths.
Together with Mortimer, Raymond found success with their opioid painkiller, OxyContin, which became the Purdue Pharma's signature drug.
Raymond was milder and more private than his brother, Mortimer.
Raymond had two children, Richard and Jonathan, before his death last year.
ILENE SACKLER
Mortimer's eldest daughter with his first wife.
She was listed as a director of Purdue's sister company, UK-based Napp Pharamaceutical Holdings, as of December 2016.
She lives in an apartment in an iconic Upper West Side which she owns.
Its total value is estimated to be more than $122million.
KATHE SACKLER
Kathe is one of the directors of Napp, a UK-based company which also sold OxyContin.
She owns two suburban properties in Connecticut which are separated by another owned by someone else and she lives in an Upper East Side townhouse with her wife, Susan Shack Sackler.
The house was owned by both Raymond and Mortimer. Their children share it.
Kathe and Ilene had a brother, Robert, is deceased.
JONATHAN AND RICHARD SACKLER
Raymond's two son by wife Beverly.
Jonathan formerly lived with his wife in Greenwich, Connecticut, in a property next to his mother's.
Richard's former family home is not far away in neighboring Stamford.
They have a cancer research center named after them at Yale and have both held positions at Purdue.
RICHARD SACKLER
Richard Sackler followed in his father's footsteps, getting his medical degree at New York University School of Medicine.
He came to Purdue after medical school, leading the research and development that ultimately produced the extended release form of OxyContin that would elevate the family's fortune to previously unfathomable.
He became president of Purdue in 1991, pioneering marketing campaigns that enticed droves of medical professionals to buy Purdue's opioid.
Richard became co-chairman in 2003, by which point $1.6 billion in OxyContin had been sold.
His marketing schemes sparked suspicion, and in 2015, Richard was deposed before his company paid out a $24 million settlement.
The company appealed in 2017, but the case has not moved forward.
ELIZABETH SACKLER
Arthur's daughter has publicly and persistently attempted to distance herself from branch of her family that has profited from OxyContin.
Elizabeth is a licensed psychiatrist and well-known philanthropist.
She is the founder of an eponymous Center for Feminist Art at the Brooklyn Museum in New York.
She has previously expressed disgrace for her uncles' business.
Elizabeth has previously told DailyMail.com: 'I, nor my siblings, nor my children have ever owned or benefited from Purdue Pharma or OxyContin or oxycodone.
'It's another branch of the family.'
BEVERLY AND THERESA SACKLER
Theresa, 69, owns a $45million Upper East Side apartment building but lives mostly in the UK on a 10-acre estate in the Berkshire countryside.
She is known in the UK as Dame Theresa Sackler, a title she was awarded for her sustained philanthropy and support of the arts.
Theresa is more visible than her sister-in-law.
Beverly, 94, is Raymond's widow. She lives on a Greenwich, Connecticut waterfront estate which has an estimated land and property value of almost $50million. She also owns a 17-floor Fifth Avenue building in Manhattan.
When her husband was still alive, they donated the Raymond and Beverly Sackler Institute for Biological, Physical and Engineering Sciences at Yale. It now employs 50 people across 20 departments.
MORTIMER DAVID ALFONS SACKLER
Mortimer the only son of founding brother Mortimer, Mortimer II's mother is Gertraud Wimmer, Mortimer's second wife.
Mortimer David owns a luxury condo building in Boston and lives in New York City with his 42-year-old wife Jacqueline.
The couple are a regular fixture on the Manhattan social circuit.
DAVID AND JOSS SACKLER
David is intensely private but his wife, Joss, is not.
She runs the members-only women's social club, LBV.
Among its events are group workouts at the model haven gym Dog Pound and talks such as 'how to have the money talk with your kids.'
English (US)